Doctors warned over NOACs in antiphospholipid syndrome
Regulators are warning about the use of non-vitamin K antagonist oral anticoagulants in patients with antiphospholipid syndrome.
Product information is being updated to include new data about an increased risk of thrombotic events in patients diagnosed with the syndrome, the TGA says in a safety alert.
The non-vitamin K antagonist oral anticoagulants (NOACs) marketed in Australia are apixaban (Eliquis), dabigatran etexilate (Pradaxa) and rivaroxaban (Xarelto).
The warning comes after a trial showed an increase in the risk of recurrent